Case report: ICI-induced hepatitis and myositis with aspergillosis
Cornelia Banciu-Odell, Olivia Castillo, Liang Yu and 3 more
Oncolog-Hematolog.ro · 2025
doi:10.26416/onhe.71.2.2025.10792 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
We report the case of a 41-year-old woman with metastatic melanoma who developed grade 4 immune checkpoint inhibitor (ICI)-induced hepatitis and autoimmune myositis following combination therapy with nivolumab and ipilimumab. Liver biopsy confirmed the diagnosis, and her hepatitis proved refractory to high-dose corticosteroids, requiring escalation to mycophenolate mofetil (MMF) and subsequently tacrolimus. She also developed bilateral lower extremity weakness consistent with immune-related myositis, and she was diagnosed with pulmonary aspergillosis during hospitalization. This case highlights the importance of early recognition, tissue diagnosis, multidisciplinary coordination, and proactive infection monitoring in the management of high-grade immune-related adverse events (irAEs).
Abstract licence: CC BY
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.